Neuroimaging Studies

神经影像学研究

• 批准号: 8375651
• 负责人: Francis Joseph McClernon
• 金额: $ 8.3万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8375651
• 关键词: Abstinence; Adult; Amygdaloid structure; Anterior; Behavioral; Blood; Brain; Brain region; Bupropion; Cause of Death; Cerebrovascular Circulation; Cerebrum; Cigarette; Clinical; Clinical Trials; Control Groups; Cues; Data; Development; Functional Magnetic Resonance Imaging; Future; Goals; Image; Infusion procedures; Intervention; Investigation; Measures; Metabolic; Outcome; Participant; Pharmaceutical Preparations; Pharmacotherapy; Placebos; Psychological reinforcement; Randomized; Recruitment Activity; Relapse; Research Personnel; Rosa; Sampling; Scanning; Screening procedure; Smoke; Smoker; Smoking; Structure; TNFRSF5 gene; Techniques; Time; Withdrawal; Withholding Treatment; Work; addiction; arm; base; cigarette smoking; cingulate gyrus; cue reactivity; design; disability; effective therapy; experience; improved; insight; interest; neuroimaging; neuromechanism; nicotine patch; nicotine replacement; preclinical study; randomized trial; relating to nervous system; response; smoking cessation; smoking relapse; success; therapy design; treatment effect; treatment response; treatment strategy; varenicline

The primary aim of the proposed center is to develop and evaluate pre-cessafion adapfive treatments for cigarette addiction. The overarching goal of this project is to evaluate the neural mechanisms that underiie pre-cessation medication effects. In a design paralleling Project 1. Clinical Trials (PD: Rose), 100 smokers will be assigned to one of four treatment arms. In all four arms, participants will confinue to smoke their usual brand of cigarettes in the two weeks prior to quitting smoking. The control (CNTRL) group will wear a placebo patch in the two weeks prior to their quit date. A second group will wear a 21 mg/d patch for the two weeks prior to the quit date (NRT-Only). A third group will switch from wearing a nicotine patch to taking varenicline in the second week (NRT¿¿VAR). A fourth group will take bupropion SR in addition to NRT in the second week (NRT+BUP). Participants will be scanned at tiaseline and again 12 hrs after quitting smoking. During scanning, we will measure brain reactivity to smoking cues and cerebral blood fiow. Common and unique effects of pre-cessation pharmacotherapies will be identified. Based on preliminary data, we hypothesize that pre-cessation treatment will result in lower brain reactivity to smoking cues and cerebral blood flow following quitfing smoking. We also hypothesize that baseline brain funcfion will be predictive of pre- and post-quit treatment response. The proposed project builds upon the investigative team's experience and is highly integrated with the center's other projects and cores.

该中心的主要目的是开发和评估戒烟前的烟瘾适应性治疗。该项目的总体目标是评估戒烟前药物作用的神经机制。在与项目 1. 临床试验（PD：Rose）并行的设计中，100 名吸烟者将被分配到四个治疗组之一。在所有四个组中，参与者将在戒烟前两周内继续吸常用品牌的香烟。对照组 (CNTRL) 将在戒烟日期前两周佩戴安慰剂贴片。第二组将在戒烟日期前两周佩戴 21 毫克/天的贴片（仅限 NRT）。第三组将在第二周从佩戴尼古丁贴片改为服用伐尼克兰（NRT¿¿VAR）。第四组将在第二周除了 NRT 之外还服用安非他酮 SR（NRT+BUP）。参与者将在 tiaseline 接受扫描，并在戒烟 12 小时后再次接受扫描。 在扫描过程中，我们将测量大脑对吸烟线索的反应和脑血流量。将确定戒烟前药物治疗的常见和独特效果。根据初步数据，我们假设戒烟前治疗将导致戒烟后大脑对吸烟线索的反应性和脑血流量降低。我们还假设基线脑功能将预测戒烟前和戒烟后的治疗反应。拟议的项目建立在调查团队的经验之上 并与中心的其他项目和核心高度集成。